Identifies prognostic genes in lung adenocarcinoma via transcriptome analysis and Mendelian randomization, suggesting potential therapeutic targets.
Background Lung adenocarcinoma (LUAD) is a prevalent and aggressive subtype of lung cancer, with a 5-year survival rate below 20% due to late-stage diagnosis and drug resistance. Endoplasmic reticulum stress (ERS) and butyrate metabolism (BM) play critical roles in tumor progression, but their co-regulatory features in LUAD remain unclear. Methods This study integrated single-cell transcriptome analysis and Mendelian randomization (MR) to identify prognostic genes associated with ERS and BM in LUAD. Public datasets were analyzed using weighted gene co-expression network analysis, differential expression analysis, and MR. A risk model and nomogram were constructed, and immune microenvironment, gene set enrichment, and single-cell analyses were performed to validate findings. Moreover, the expression of prognostic genes was validated in different Non-small cell lung cancer (NSCLC) cell lines through reverse transcription quantitative polymerase chain reaction (RT-qPCR). Results Seven prognostic genes ( VDAC1 , TXNRD1 , GDF15 , TRIB3 , LPL , KCNQ1 , PKP2 ) were identified, RT-qPCR assays confirmed that these genes exhibited significant expression differences in different NSCLC cell lines. The risk model demonstrated that low-risk patients had significantly better survival outcomes. The nomogram exhibited strong predictive accuracy for 1-, 3-, and 5-year survival. Enriched pathways in high-risk patients included olfactory transduction, while low-risk patients showed enrichment in ribosome and complement-coagulation cascades. Immune profiling revealed 13 differentially abundant immune cell types, including M1 macrophages. Single-cell analysis identified macrophages as key players in LUAD. Notably, VDAC1 , TXNRD1 , and LPL were highly expressed during early macrophage differentiation. Conclusion This study identifies seven ERS- and BM-related prognostic genes and highlights macrophages as pivotal in LUAD progression, the expression differences of candidate genes were verified by RT-qPCR assay. These findings provide novel insights into LUAD diagnosis, prognosis, and potential therapeutic targets, offering a foundation for precision medicine strategies. Further validation in clinical cohorts and functional studies is warranted to translate these discoveries into clinical applications.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: